Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 865101, 9 pages
http://dx.doi.org/10.1155/2015/865101
Review Article

Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?

1Cancer Research UK Centre, University of Southampton, Southampton SO16 6YD, UK
2Department for Health Economics, University of Bielefeld, 33501 Bielefeld, Germany
3PAREXEL International, 160 Euston Road, London NW1 2DX, UK
4Bristol-Myers Squibb, Route 206 and Province Line Road, Princeton, NJ 08543, USA

Received 7 July 2014; Accepted 31 October 2014

Academic Editor: Swaleha Zubair

Copyright © 2015 Peter Johnson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Sridhara, J. R. Johnson, R. Justice, P. Keegan, A. Chakravarty, and R. Pazdur, “Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007,” Journal of the National Cancer Institute, vol. 102, no. 4, pp. 230–243, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. S. A. Rosenberg, “Raising the bar: the curative potential of human cancer immunotherapy,” Science Translational Medicine, vol. 4, no. 127, Article ID 127ps8, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Schadendorf, F. S. Hodi, C. Robert et al., “Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma,” in Proceedings of the European Cancer Congress (ECC '13), Abs 24LBA, 2013.
  4. J. M. Kirkwood, L. H. Butterfield, A. A. Tarhini, H. Zarour, P. Kalinski, and S. Ferrone, “Immunotherapy of cancer in 2012,” CA: A Cancer Journal for Clinicians, vol. 62, no. 5, pp. 309–335, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. O. J. Finn, “Immuno-oncology: understanding the function and dysfunction of the immune system in cancer,” Annals of Oncology, vol. 23, supplement 8, pp. viii6–viii9, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. J. D. Wolchok, F. S. Hodi, J. S. Weber et al., “Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma,” Annals of the New York Academy of Sciences, vol. 1291, no. 1, pp. 1–13, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. D. McDermott, J. Haanen, T. T. Chen, P. Lorigan, and S. O'Day, “Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20),” Annals of Oncology, vol. 24, no. 10, pp. 2694–2698, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. F. S. Hodi, S. L. Topalian, J. Brahmer et al., “Survival and long-term safety in patients with advanced solid tumors receiving nivolumab (anti-PD-1; BMS-936558; ONO-4538),” in Proceedings of the European Cancer Congress (ECC '13), Abs 880P, 2013.
  9. O. Hamid, C. Robert, A. Daud et al., “Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma,” The New England Journal of Medicine, vol. 369, no. 2, pp. 134–144, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. J. C. Soria, C. Cruz, R. Bahleda et al., “Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1),” in Proceedings of the CC Congress, Abstract 3408, 2013.
  11. D. N. Lakdawalla, J. A. Romley, Y. Sanchez, J. R. Maclean, J. R. Penrod, and T. Philipson, “How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies,” Health Affairs, vol. 31, no. 4, pp. 676–682, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Othus, B. Barlogie, M. L. LeBlanc, and J. J. Crowley, “Cure models as a useful statistical tool for analyzing survival,” Clinical Cancer Research, vol. 18, no. 14, pp. 3731–3736, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. J. V. Melo and D. M. Ross, “Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure?” in ASH Education Program Book, pp. 136–142, 2011. View at Google Scholar
  14. F.-X. Mahon, “Is going for cure in chronic myeloid leukemia possible and justifiable?” Hematology/The Education Program of the American Society of Hematology, vol. 2012, pp. 122–128, 2012. View at Google Scholar · View at Scopus
  15. E. Paietta, “Assessing minimal residual disease (MRD) in leukemia: a changing definition and concept?” Bone Marrow Transplantation, vol. 29, no. 6, pp. 459–465, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Goldman and M. Gordon, “Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?” Leukemia & Lymphoma, vol. 47, no. 1, pp. 1–7, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Ribas, P. Hersey, M. R. Middleton et al., “New challenges in endpoints for drug development in advanced melanoma,” Clinical Cancer Research, vol. 18, no. 2, pp. 336–341, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. M. di Maio, C. Gallo, E. de Maio et al., “Methodological aspects of lung cancer clinical trials in the era of targeted agents,” Lung Cancer, vol. 67, no. 2, pp. 127–135, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. C. A. Dooms and J. F. Vansteenkiste, “Treatment of patients with advanced non-small cell lung cancer,” American Journal of Cancer, vol. 3, no. 5, pp. 281–290, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. T. E. Hutson, “Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence,” The Oncologist, vol. 16, supplement 2, pp. 14–22, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. S. K. Pal and R. A. Figlin, “Targeted therapies for renal cell carcinoma: understanding their impact on survival,” Targeted Oncology, vol. 5, no. 2, pp. 131–138, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Bilusic and J. L. Gulley, “Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines,” Cancer Immunology, Immunotherapy, vol. 61, no. 1, pp. 109–117, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. F. S. Hodi, S. J. O'Day, D. F. McDermott et al., “Improved survival with ipilimumab in patients with metastatic melanoma,” The New England Journal of Medicine, vol. 363, no. 8, pp. 711–723, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. S. L. Topalian, F. S. Hodi, J. R. Brahmer et al., “Safety, activity, and immune correlates of anti-PD-1 antibody in cancer,” The New England Journal of Medicine, vol. 366, no. 26, pp. 2443–2454, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Davies, A. Briggs, J. Schneider et al., “The ends justify the mean: outcome measures for estimating the value of new cancer therapies,” Health Outcomes Research in Medicine, vol. 3, no. 1, pp. e25–e36, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. L. M. Ellis, D. S. Bernstein, E. E. Voest et al., “American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes,” Journal of Clinical Oncology, vol. 32, no. 12, pp. 1277–1280, 2014. View at Google Scholar
  27. J. S. De Bono, S. Oudard, and M. Ozguroglu, “Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial,” The Lancet, vol. 377, no. 9767, pp. 1147–1154, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Oudard, A. Joulain, A. de Geer, and O. Sartor, “Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: estimating mean overall survival (OS) for health economic analyses from a phase III trial (TROPIC),” Journal of Clinical Oncology, vol. 29, supplement 7, ASCO, abstract 128, 2011. View at Google Scholar
  29. D. Y.-S. Kuo, S. V. Blank, P. J. Christos et al., “Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: a New York Cancer Consortium Study,” Gynecologic Oncology, vol. 116, no. 3, pp. 442–446, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. J. F. S. Miguel, R. Schlag, N. K. Khuageva et al., “Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma,” Journal of Clinical Oncology, vol. 31, no. 4, pp. 448–455, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Lopez-Chavez, T. Young, S. Fages et al., “Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the eastern cooperative oncology group 4599 study: results of an exploratory analysis,” Journal of Thoracic Oncology, vol. 7, no. 11, pp. 1707–1712, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. P. C. Lambert, J. R. Thompson, C. L. Weston, and P. W. Dickman, “Estimating and modeling the cure fraction in population-based cancer survival analysis,” Biostatistics, vol. 8, no. 3, pp. 576–594, 2007. View at Publisher · View at Google Scholar · View at Zentralblatt MATH · View at Scopus
  33. N. R. Smoll, K. Schaller, and O. P. Gautschi, “The cure fraction of glioblastoma multiforme,” Neuroepidemiology, vol. 39, no. 1, pp. 63–69, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. P. C. Lambert, P. W. Dickman, P. Österlund, T. Andersson, R. Sankila, and B. Glimelius, “Temporal trends in the proportion cured for cancer of the colon and rectum: a population-based study using data from the Finnish Cancer Registry,” International Journal of Cancer, vol. 121, no. 9, pp. 2052–2059, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. L. Huang, K. A. Johnson, A. B. Mariotto, J. J. Dignam, and E. J. Feuer, “Population-based survival-cure analysis of ER-negative breast cancer,” Breast Cancer Research and Treatment, vol. 123, no. 1, pp. 257–264, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. European Medicines Agency Oncology Working Party, “Guideline on the evaluation of anticancer medicinal products in man,” 2014, http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/01/WC500137128.pdf.
  37. National Institute for Health and Clinical Excellence Final Appraisal Determination, “Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma,” December 2013, http://www.nice.org.uk/nicemedia/live/12092/61322/61322.pdf.
  38. B. Sherrill, J. A. Kaye, R. Sandin, J. C. Cappelleri, and C. Chen, “Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology,” OncoTargets and Therapy, vol. 5, pp. 287–296, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. J. D. Wolchok, A. Hoos, S. O'Day et al., “Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria,” Clinical Cancer Research, vol. 15, no. 23, pp. 7412–7420, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Hoos, “Evolution of end points for cancer immunotherapy trials,” Annals of Oncology, vol. 23, supplement 8, Article ID mds263, pp. viii47–viii52, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. P. W. Kantoff, C. S. Higano, N. D. Shore et al., “Sipuleucel-T immunotherapy for castration-resistant prostate cancer,” The New England Journal of Medicine, vol. 363, no. 5, pp. 411–422, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. P. W. Kantoff, T. J. Schuetz, B. A. Blumenstein et al., “Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer,” Journal of Clinical Oncology, vol. 28, no. 7, pp. 1099–1105, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. G. Bedard, L. Zeng, H. Lam et al., “Meaningful change in oncology quality-of-life instruments: a systematic literature review,” Expert Review of Pharmacoeconomics & Outcomes Research, vol. 12, no. 4, pp. 475–483, 2012. View at Publisher · View at Google Scholar · View at Scopus